Sanofi US News

• Clinical trials will be conducted at Centers of Excellence at four historically Black medical schools
• The Beacon of Hope program aims to strengthen clinical trial capabilities, improve the quality and inclusivity of clinical trials and help rebuild trust in the healthcare system within Black communities
• Initiative is part of Sanofi's broader commitment to increase clinical trial diversity throughout the entire ecosystem – from study design and eligibility criteria to site selection, recruitment materials, and engagement with local communities

First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms

- A median annualized bleeding rate (ABR) of 0.0 was reported in the overall study population during fitusiran prophylaxis (80 mg monthly)

- Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia A

Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins

Results of nationally representative survey come as the ACIP evaluates data to provide guidance for flu vaccines in this vulnerable population

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood